| Name | CAS NO. | Usage |
| AICAR | 2627-69-2 | acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown |
| MK2866 | 841205-47-8 | medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy. |
| MK-677 | 15972-10-0 | A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly |
| LGD-4033 | 1165910-22-4 | pharmacological profile similar to that of enobosarm, Ostarine,MK-2866 |
| GW1516 | 317318-70-0 | For obesity, diabetes, dyslipidemia and cardiovascular disease |
| Andarine(S4) | 401900-40-0 | partial agonist, intended mainly for treatment of benign prostatic hypertrophy |
| SR9009 | 1379686-30-2 | under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice |
| RAD140 | 1182367-47-0 | New generation for gaining mass and cutting edges |
| YK11 | 431579-34-9 | YK11: a SARM and myostatin inhibitor in one |